Spotlight on TB

What Does a Borderline T-SPOT.®TB Test Result Mean?

From Oxford Immunotec’s Spotlight Series on TB, a review of the Borderline result category of the T-SPOT.®TB test.

(run time: 1m52s)


Rheumatology Practice & Mycobacterial Diseases: Awareness, Screening, Treatment & Sequelae

Join Dr. Juzar Ali as he provides an update on identification, screening, and management of TB and non-tuberculosis mycobacteria (NTM) in non-HIV immune compromised patients seen specially in Rheumatology practices. Dr. Ali also discusses practical issues faced by physicians taking care of patients being treated with immune suppressive medications and biologic agents.

(run time: presentation 40m29s, Q&A session 1m17s)

Cell-mediated Immunity: Testing for SARS-CoV-2

Join Dr. Ruth Brignall as she reviews the immunology of SARS-CoV-2 infection and discusses how a cell-mediated immunity test could help to develop our understanding of immune responses to SARS-CoV-2 and provide additional insights into potential protective immunity against reinfection.

(run time: presentation 37m35s, Q&A session 7m45s)

Diagnostic Update: Tuberculosis in Children

Join Ana M. Alvarez, MD as she presents an update on the diagnosis of latent Mycobacterium tuberculosis (TB) infection in children. Dr. Alvarez will review illustrative cases from pediatric patients, and she will discuss FAQs about TB infection in children.

At the conclusion of this program, participants should be able to:

  • Define latent TB infection (LTBI)
  • List the tests currently available to diagnose latent TB infection in children, and discuss their advantages and disadvantages
  • Discuss the appropriate work up for pediatric patients with suspected TB infection

(run time: presentation 64m46s, Q&A session 8m34s)

Moving Beyond the Tuberculin Skin Test (TST)

The Tuberculin Skin Test was developed in 1907. While it was highly effective in the US for most of the 20th century, it no longer meets the needs of the 21st century.

At the end of the presentation and discussion participants will be able to:

  • Describe the diagnostic immunological testing options available for TB screening
  • Outline current screening recommendations
  • Evaluate the differences, advantages, and disadvantages among TB screening options
  • Identify specific advantages of IGRA testing in challenging clinical, public health, and employee health settings in the US

(run time: presentation 42m21s, Q&A session 39m9s)

Diagnosing TB in the Immunocompromised: What’s New?

Join Dr. Roy Chemaly as he discusses effective TB testing methods in the immunocompromised population. At the end of the presentation and discussion participants will be able to:

  • Review current tuberculosis (TB) statistics
  • Differentiate between the 3 TB testing methods
  • Identify what constitutes immunocompromised patient populations
  • Identify the clinical utility of interferon-gamma release assays (IGRAs) in immunocompromised patient populations

(run time: presentation 48m34s, Q&A session 12m)

Expert Series

Expert Series with Dr. Roy Chemaly

In this two-part Expert video series, Dr. Roy Chemaly answers Frequently Asked Questions (FAQs) about diagnosing latent TB infection (LTBI) in immunocompromised patient populations.

Video 1: Answers to FAQs: LTBI Testing Methodologies (run time: 9m, 52s)

Video 2: Answers to FAQs: Immunocompromised Patient Populations (run time: 10m, 18s)

Expert Series with Dr. Juzar Ali

In this two-part Expert video series, Dr. Juzar Ali discusses the T-SPOT®.TB test’s Borderline result category and its clinical utility in helping to reduce the risk of misclassifying patients whose results are around the test’s established cut-offs for Positive or Negative.

Video 1: What is the Borderline? (run time: 16m, 15s)

Video 2: Case Studies (run time: 8m, 33s)


Short Takes on Tuberculosis

Tuberculosis (TB), though an ancient disease, is still a major cause of death and a challenging public health problem worldwide.

The Short Takes on Tuberculosis video series features brief educational segments covering TB infection, diagnosis, and public health impact.

Video 1: Tuberculosis: Ancient Disease, 21st-Century Crisis

Video 2: Diagnosing TB: Understanding Available Diagnostic Tests

Video 3: Diagnosing TB: Understanding Important Differences in IGRA Test Design

Osmosis Video: Mycobacterium tuberculosis

Author: Rishi Desai, MD, MPH, Pediatric Infectious Disease Attending, Stanford University, Palo Alto, California; Chief Medical Officer, Osmosis

A comprehensive overview of Mycobacterium tuberculosis in an engaging educational video from Osmosis.

To view the video, visit the Osmosis website at

Please note: Osmosis does not support Internet Explorer. Recommended browsers include Google Chrome, Firefox, Safari, Opera.

Content Reviewers: Rishi Desai, MD, MPH; Tanner Marshall, MS

Copyright Knowledge Diffusion, Inc.

(run time 10m57s)

Tuberculosis Survivors

In this video mini-series, six TB survivors share their personal stories and discuss the disease from a patient’s perspective.

History of TB

TB Timeline: A History of TB Testing

Here is a brief look at the history of TB testing methods, highlighting the significant milestones for advancements in technology and clinical practice.

Please note: This resource does not support Internet Explorer. Recommended browsers include Google Chrome, Firefox, Safari, Opera.

Global T cell Experts

More resources from the Global T cell Expert Consortium (GTEC)

The Global T cell Expert Consortium is a community of experts in T cell and vaccine research, epidemiology and global public health that aims to be the leading voice for T cell expertise during and beyond the current COVID-19 pandemic.

The consortium aims to advance the frontiers of T cell research and education by providing a platform for global experts to come together, share their expertise and insights, and collaborate to address the unmet needs and remaining challenges in T cell testing and research. The consortium will educate on T cells by generating a series of publicly available resources such as webinars and podcasts.

The agenda of this initiative and its associated educational content are owned and driven by our consortium experts, with support from Oxford Immunotec.


Leaving Oxford Immunotec Medical Education

You are now leaving the website of Oxford Immunotec Medical Education. External links are being provided as a convenience and for informational purposes only; they do not constitute an endorsement or an approval by Oxford Immunotec Medical Education of any of the products, services or opinions of the corporation or organization or individual. Oxford Immunotec Medical Education bears no responsibility for the accuracy, legality or content of the external site or for that of subsequent links.
Contact the external site for answers to questions regarding its content.

Are you sure you want to visit ?

Yes No